Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Cost of Revenue (2016 - 2025)

Guided Therapeutics' Cost of Revenue history spans 15 years, with the latest figure at $22000.0 for Q3 2025.

  • For Q3 2025, Cost of Revenue fell 71.05% year-over-year to $22000.0; the TTM value through Sep 2025 reached $76000.0, down 46.48%, while the annual FY2024 figure was $5000.0, 91.94% down from the prior year.
  • Cost of Revenue for Q3 2025 was $22000.0 at Guided Therapeutics, down from $51000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $140000.0 in Q2 2024 and bottomed at -$76000.0 in Q4 2023.
  • The 5-year median for Cost of Revenue is $36000.0 (2021), against an average of $31647.1.
  • The largest annual shift saw Cost of Revenue tumbled 148.48% in 2022 before it surged 7200.0% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $99000.0 in 2021, then crashed by 148.48% to -$48000.0 in 2022, then tumbled by 58.33% to -$76000.0 in 2023, then skyrocketed by 103.95% to $3000.0 in 2024, then skyrocketed by 633.33% to $22000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Cost of Revenue are $22000.0 (Q3 2025), $51000.0 (Q2 2025), and $3000.0 (Q4 2024).